Patent application number | Description | Published |
20090041748 | Fibrinogen-Based Tissue Adhesive Containing an Elastase Inhibitor - The present invention provides a fibrinogen-based tissue adhesive which contains an elastase inhibitor. | 02-12-2009 |
20090275011 | SESSILE STEM CELLS - Sterile, virally safe, heterologous, homologous, isologous or autologous tissue, tissue-typed or not tissue-typed, which contains predifferentiated and/or differentiable sessile stem cells and which can be used for wound closure and/or promotion of wound healing. | 11-05-2009 |
20110009324 | Stable Therapeutic Proteins - The invention relates to storable medicaments produced from pharmaceutical active ingredient preparations which are virus safe. Said medicaments contain at least one intact therapeutic protein obtained from plasma or by means of genetic engineering, as an active pharmaceutical substance. Said active ingredient preparations contain active enzymes, especially proteases, which are either free or bound to the substrates thereof and act against the therapeutic protein(s) present. | 01-13-2011 |
20110190812 | FIBRINOGEN-BASED TISSUE ADHESIVE CONTAINING AN ELASTASE INHIBITOR - The present invention provides a fibrinogen-based tissue adhesive which contains an elastase inhibitor. | 08-04-2011 |
Patent application number | Description | Published |
20090123453 | Pharmaceutical Preparations And Medicines Capable Of Generating, And/Or Containing, Thrombin - The invention relates to a pharmaceutical active ingredient preparation for producing a medicament that contains thrombin or has a thrombin-generating capacity and compositions comprising thereof. The inventive preparation contains: (A) prothrombin obtained from plasma or by means of genetic engineering (coagulation factor II), (B) coagulation factors V, VIII, IX, X obtained from plasma or by means of genetic engineering, which can be at least partially in the activated state, and coagulation factor X1a obtained from plasma or by means of genetic engineering, and (C) phospholipids which are safe from prions and contribute to the clotting process, said phospholipids being optionally contained in liposomes. | 05-14-2009 |
20110114524 | STORAGE-STABLE, FUNCTIONALLY INTACT FIBRINOGEN - Method for the production of a fibrinogen solution from an aqueous solution that contains functionally intact fibrinogen and is contaminated with profibrin and/or fibrin monomers and/or fibrin monomer complexes and/or fibrin split products, characterized in that the contaminations are precipitated using a non-denaturing precipitating agent at a temperature ranging from −4° to +4° and calcium ion activity not exceeding that of a 1,000 μM CaCl | 05-19-2011 |
20110318330 | MEDICINAL PRODUCTS FOR THE TREATMENT OF BLOOD COAGULATION DISORDERS - A virally safe, thrombin-free factor-Xla concentrate or a coagulation factor concentrate which contains factor XIa as an active pharmaceutical ingredient and which is obtained by fractionation of plasma or serum or by genetic engineering and is suitable for the treatment of coagulation disorders attributable to diminished and/or delayed thrombin formation. | 12-29-2011 |
20150023947 | MEDICINAL PRODUCTS FOR THE TREATMENT OF BLOOD COAGULATION DISORDERS - A virally safe, thrombin-free factor-XIa concentrate or a coagulation factor concentrate which contains factor XIa as an active pharmaceutical ingredient and which is obtained by fractionation of plasma or serum or by genetic engineering and is suitable for the treatment of coagulation disorders attributable to diminished and/or delayed thrombin formation. | 01-22-2015 |